← Leaderboards
William Laurence Dahut
Clinical Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Thalidomide”
- Walter John Curran · Thomas Jefferson University$26,641,549
- William G Kaelin · Dana-Farber Cancer Institute$9,761,992
- Patricia M Rodier · University Of Rochester$5,610,286
- Michele Pagano · New York University School Of Medicine$5,565,349
- Keith R. McCrae · Case Western Reserve University$5,447,978
- Peter Leif Bergsagel · Weill Medical College Of Cornell Univ$5,124,352
Research focus
ThalidomideSmall MoleculeProstate-Specific AntigenGenitourinary SystemEvaluationSeriesMalignant NeoplasmsTumorResponseMalignant Neoplasm Of ProstateNovel TherapeuticsCancer EtiologyNci Center For Cancer ResearchProgramsImageHormone TherapyLaboratoriesAmericanMolecular ImagingCessation Of LifePreclinical StudyChemotherapyMonoclonal AntibodiesAngiogenesis Inhibitors
Grant awards (18)
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$426,153
ZIA · FY2022 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$534,576
ZIA · FY2021 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$488,637
ZIA · FY2020 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$470,418
ZIA · FY2019 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$899,708
ZIA · FY2018 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$871,023
ZIA · FY2017 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$929,563
ZIA · FY2016 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$738,484
ZIA · FY2015 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$492,502
ZIA · FY2012 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$485,992
ZIA · FY2011 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$531,416
ZIA · FY2010 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$695,031
ZIA · FY2009 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$397,882
Z01 · FY2008 · CA · contact PI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies$727,088
Z01 · FY2007 · CA · contact PI
Evaluation of Novel Therapeutics for Genitourinary Malig$0
Z01 · FY2003 · SC
The Evaluation of Novel Therapeutics for Genitourinary M$0
Z01 · FY2002 · SC
Evaluation of Therapeutics for Genitourinary Malignancy$0
Z01 · FY2001 · SC
Novel Therapeutics for Genitourinary Malignancies$0
Z01 · FY2000 · SC